2,585
Views
0
CrossRef citations to date
0
Altmetric
Original Research

Assessment of Quality of Life 8-Dimension (AQoL-8D): translation, validation, and application in two Dutch trials in patients with epilepsy and schizophrenia

ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon & ORCID Icon show all
Pages 795-803 | Received 10 Jun 2021, Accepted 14 Sep 2021, Published online: 26 Sep 2021

References

  • Howren MB. Quality-Adjusted Life Years (QALYs). In: Gellman MD, Turner JR, editors. Encyclopedia of behavioral medicine. New York (NY): Springer; 2013. p. 1605–1606.
  • Lorgelly PK, Doble B, Rowen D, et al. Condition-specific or generic preference-based measures in oncology? A comparison of the EORTC-8D and the EQ-5D-3L. Qual Life Res. 2017;26(5):1163–1176.
  • Halling Hastrup L, Nordentoft M, Hjorthoj C, et al. Does the EQ-5D measure quality of life in schizophrenia? J Ment Health Policy Econ. 2011;14(4):187–196.
  • Brazier J. Is the EQ-5D fit for purpose in mental health? Br J Psychiatry. 2010;197(5):348–349.
  • (ISPOR), I. S. f. P. a. O. R. Pharmacoeconomics guidelines around the World; 2021.
  • Lamers LM, Bouwmans CA, van Straten A, et al. Comparison of EQ-5D and SF-6D utilities in mental health patients. Health Econ. 2006;15(11):1229–1236.
  • Van de Willige G, Wiersma D, Nienhuis FJ, et al. Changes in quality of life in chronic psychiatric patients: a comparison between EuroQol (EQ-5D) and WHOQoL. Qual Life Res. 2005;14(2):441–451.
  • Brazier J, Roberts J, Tsuchiya A, et al. A comparison of the EQ-5D and SF-6D across seven patient groups. Health Econ. 2004;13(9):873-884.
  • Brazier J, Connell J, Papaioannou D, et al. A systematic review, psychometric analysis and qualitative assessment of generic preference-based measures of health in mental health populations and the estimation of mapping functions from widely used specific measures. Health Technol Assess. 2014;18(34):vii–viii, xiii–xxv, 1–188.
  • Mulhern B, Pink J, Rowen D, et al. Comparing generic and condition-specific preference-based measures in epilepsy: EQ-5D-3L and NEWQOL-6D. Value Health. 2017;20(4):687–693.
  • Mulhern BM, Barkham C, Knapp M, et al. Using preference based measures in mental health conditions: the psychometric validity of the EQ-5D and SF-6D. The University of Sheffield; 2013. (Health Economics and Decision Science (HEDS) Discussion Paper).
  • Papaioannou D, Brazier J, Parry G. How valid and responsive are generic health status measures, such as EQ-5D and SF-36, in schizophrenia? A systematic review. Value Health. 2011;14(6):907–920.
  • Goranitis I, Coast J, Day E, et al. Measuring health and broader well-being benefits in the context of opiate dependence: the psychometric performance of the ICECAP-A and the EQ-5D-5L. Value Health. 2016;19(6):820–828.
  • Brooks R. The EuroQol group after 25 years. 2013.
  • Bharmal M, Thomas J III. Comparing the EQ‐5D and the SF‐6D descriptive systems to assess their ceiling effects in the US general population. Value Health. 2006;9(4):262–271.
  • van Hout B, Janssen MF, Feng YS, et al. Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. Value Health. 2012;15(5):708–715.
  • Janssen M, Pickard AS, Golicki D, et al. Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L across eight patient groups: a multi-country study. Qual Life Res. 2013;22(7):1717–1727.
  • Millier A, Clay E, Charaf I, et al. Patient reported outcomes instruments in schizophrenia: a review of psychometric properties. Open J Med Psychol. 2014;3(2):16.
  • Karow A, Wittmann L, Schottle D, et al. The assessment of quality of life in clinical practice in patients with schizophrenia. Dialogues Clin Neurosci. 2014;16(2):185–195.
  • Adams J, Crowley CLR,S, Nand V, et al. Valuation of schizophrenia-related health states by the general population using the AQoL, time trade-off and visual analogue scales. ISPOR 10th Annual International Meeting; Washington (DC); 2005.
  • Mukuria C, Young T, Keetharuth A, et al. Sensitivity and responsiveness of the EQ-5D-3L in patients with uncontrolled focal seizures: an analysis of Phase III trials of adjunctive brivaracetam. Qual Life Res. 2017;26(3):749–759.
  • Selai C, Elstner K, Trimble M. Quality of life pre and post epilepsy surgery. Epilepsy Res. 1999;38(1):67–74.
  • Wijnen BFM, Mosweu I, Majoie M, et al. A comparison of the responsiveness of EQ-5D-5L and the QOLIE-31P and mapping of QOLIE-31P to EQ-5D-5L in epilepsy. Eur J Health Econ. 2018;19(6):861-870.
  • Campbell JA, Palmer AJ, Venn A, et al. A head-to-head comparison of the EQ-5D-5L and AQoL-8D multi-attribute utility instruments in patients who have previously undergone bariatric surgery. Patient. 2016;9(4):311–322.
  • Hawthorne G, Richardson J, Osborne R. The Assessment of Quality of Life (AQoL) instrument: a psychometric measure of health-related quality of life. Qual Life Res. 1999;8(3):209–224.
  • Hawthorne G, Richardson J, Day NA. A comparison of the Assessment of Quality of Life (AQoL) with four other generic utility instruments. Ann Med. 2001;33(5):358–370.
  • Richardson J, Sinha K, Iezzi A, et al. Modelling utility weights for the Assessment of Quality of Life (AQoL)-8D. Qual Life Res. 2014;23(8):2395–2404.
  • Richardson J, Iezzi A, Khan MA, et al. Validity and reliability of the Assessment of Quality of Life (AQoL)-8D multi-attribute utility instrument. Patient. 2014;7(1):85–96.
  • Wijnen B, Leenen LA, de Kinderen RJ, et al. (Cost-) effectiveness of a multi-component intervention for adults with epilepsy: study protocol of a Dutch randomized controlled trial. Value Health. 2014;17(7):A582–583.
  • Wijnen BF, Pos K, Velthorst E, et al. Economic evaluation of brief cognitive behavioural therapy for social activation in recent-onset psychosis. PloS one. 2018;13(11):e0206236.
  • Pos K, Franke N, Smit F, et al. Cognitive behavioral therapy for social activation in recent-onset psychosis: randomized controlled trial. J Consult Clin Psychol. 2019;87(2):151.
  • Devlin N, Shah KK, Feng Y, et al. Valuing health-related quality of life: an EQ-5D-5L value set for England. 2016.
  • Campbell JA, Hensher M, Neil A, et al. An exploratory study of long-term publicly waitlisted bariatric surgery patients’ quality of life before and 1 year after bariatric surgery, and considerations for healthcare planners. PharmacoEcon Open. 2018;2(1):63–76.
  • Lamers LM, McDonnell J, Stalmeier PF, et al. The Dutch tariff: results and arguments for an effective design for national EQ-5D valuation studies. Health Econ. 2006;15(10):1121–1132.
  • Versteegh MM, Vermeulen KM, Evers SM, et al. Dutch tariff for the five-level version of EQ-5D. Value Health. 2016;19(4):343–352.
  • Mokkink LB, Terwee CB, Patrick DL, et al. The COSMIN study reached international consensus on taxonomy, terminology, and definitions of measurement properties for health-related patient-reported outcomes. J Clin Epidemiol. 2010;63(7):737–745.
  • Šimkovic M, Träuble B. Robustness of statistical methods when measure is affected by ceiling and/or floor effect. PloS One. 2019;14:8.
  • Mokkink LB, Terwee CB, Patrick DL, et al. The COSMIN checklist for assessing the methodological quality of studies on measurement properties of health status measurement instruments: an international Delphi study. Qual Life Res. 2010;19(4):539–549.
  • Chen H, Cohen P, Chen S. How big is a big odds ratio? Interpreting the magnitudes of odds ratios in epidemiological studies. Commun Stat Simul Comput. 2010;39(4):860–864.
  • Liang MH. Evaluating measurement responsiveness. J Rheumatol. 1995;22(6):1191–1192.
  • Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Int J Nurs Stud. 2010;47(8):931–936.
  • Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986;1(8476):307-310.
  • Giavarina D. Understanding Bland Altman analysis. Biochem Med (Zagreb). 2015;25(2):141–151.
  • Dritsaki M, Petrou S, Williams M, et al. An empirical evaluation of the SF-12, SF-6D, EQ-5D and Michigan hand outcome questionnaire in patients with rheumatoid arthritis of the hand. Health Qual Life Outcomes. 2017;15(1):20.
  • Matza LS, Boye KS, Yurgin N. Validation of two generic patient-reported outcome measures in patients with type 2 diabetes. Health Qual Life Outcomes. 2007;5:47.
  • Marra CA, Woolcott JC, Kopec JA, et al. A comparison of generic, indirect utility measures (the HUI2, HUI3, SF-6D, and the EQ-5D) and disease-specific instruments (the RAQoL and the HAQ) in rheumatoid arthritis. Soc Sci Med. 2005;60(7):1571–1582.
  • Hofman CS, Lutomski JE, Boter H, et al.; Consortium, T.-M. R. Examining the construct and known-group validity of a composite endpoint for The Older Persons and Informal Caregivers Survey Minimum Data Set (TOPICS-MDS); A large-scale data sharing initiative. PLoS One. 2017;12(3):e0173081.
  • Davidson M. Known-groups validity. In: Michalos AC, editor. Encyclopedia of quality of life and well-being research. Dordrecht (The Netherlands): Springer; 2014. p. 3481–3482.
  • Snaith RP. The hospital anxiety and depression scale. Health Qual Life Outcomes. 2003;1:29.
  • Bouwmans C, Krol M, Severens H, et al. The iMTA productivity cost questionnaire: a standardized instrument for measuring and valuing health-related productivity losses. Value Health. 2015;18(6):753–758.
  • O’Donoghue MF, Duncan JS, Sander JW. The national hospital seizure severity scale: a further development of the Chalfont seizure severity scale. Epilepsia. 1996;37(6):563–571.
  • Ferreira LN, Ferreira PL, Ribeiro FP, et al. Comparing the performance of the EQ-5D-3L and the EQ-5D-5L in young Portuguese adults. Health Qual Life Outcomes. 2016;14(1):89.
  • Greene ME, Rader KA, Garellick G, et al. The EQ-5D-5L improves on the EQ-5D-3L for health-related quality-of-life assessment in patients undergoing total hip arthroplasty. Clin Orthop Relat Res. 2015;473(11):3383–3390.
  • Nolan CM, Longworth L, Lord J, et al. The EQ-5D-5L health status questionnaire in COPD: validity, responsiveness and minimum important difference. Thorax. 2016;71(6):493–500.
  • McClure NS, Sayah FA, Xie F, et al. Instrument-defined estimates of the minimally important difference for EQ-5D-5L index scores. Value Health. 2017;20(4):644–650.
  • Hawthorne G. Assessing utility where short measures are required: development of the short Assessment of Quality of Life-8 (AQoL-8) instrument. Value Health. 2009;12(6):948–957.
  • Hawthorne G, Korn S, Richardson JJA; Health, N. Z. J. O. P. Population norms for the AQoL derived from the 2007 Australian national survey of mental health and wellbeing. Aust N Z J Public health. 2013;37(1):7–16.
  • Holland R, Smith RD, Harvey I, et al. Assessing quality of life in the elderly: a direct comparison of the EQ‐5D and AQoL. Health Econ. 2004;13(8):793–805.
  • Cramer JA, Perrine K, Devinsky O, et al. Development and cross‐cultural translations of a 31‐item quality of life in epilepsy inventory. Epilepsia. 1998;39(1):81–88.